⚕ GalenOps CRO console
← SITE005 (FRA)

SITE005-0014

withdrawn
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE005 (FRA) (Dr. Muller) · consented 2022-03-03
Adverse events
8
Serious AEs
2
Open data queries
0
Luna dropout signal
–

Adverse events

mild assessed 2026-08-18

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-05-05 (study day 49); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-05-06 (study day 50); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-05-11 (study day 55); relationship: N

severe serious assessed 2026-08-18

Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-05-28 (study day 72); relationship: N; serious criteria: life-threatening

severe serious assessed 2026-08-18

Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-06-05 (study day 80); relationship: not assessed; serious criteria: life-threatening

mild assessed 2026-08-18

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-06-28 (study day 103); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-06-28 (study day 103); relationship: N

mild assessed 2026-08-18

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-07-03 (study day 108); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.